DDInter1796 DDInter927
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Thioridazine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Thioridazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Thioridazine {u} (Compound) binds {v} (Gene) CYP2D6
Thioridazine {u} (Compound) upregulates {v} (Gene) KDM5B
Thioridazine {u} (Compound) palliates {v} (Disease) schizophrenia
Thioridazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Thioridazine {u} (Compound) downregulates {v} (Gene) VAPB
Thioridazine {u} (Compound) causes {v} (Side Effect) Cholestasis
Thioridazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Thioridazine (Compound) resembles Prochlorperazine (Compound)
Thioridazine (Compound) resembles Ethopropazine (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Thioridazine (Compound) binds CYP2D6 (Gene)
Thioridazine (Compound) upregulates KDM5B (Gene)
Thioridazine (Compound) palliates schizophrenia (Disease)
Thioridazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Thioridazine (Compound) downregulates VAPB (Gene)
Thioridazine (Compound) causes Cholestasis (Side Effect)
Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide